Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAP NASDAQ:BCRX NASDAQ:CABA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.06-10.5%$0.09$0.04▼$0.36$15.35M2.4957.14 million shs49.26 million shsBCRXBioCryst Pharmaceuticals$8.74-0.3%$9.17$6.00▼$11.31$2.22B0.575.17 million shs2.57 million shsCABACabaletta Bio$3.44+5.2%$3.17$1.26▼$4.23$382.96M3.183.28 million shs3.29 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics0.00%0.00%0.00%0.00%-80.12%BCRXBioCryst Pharmaceuticals-2.23%-0.34%-7.68%+20.80%-15.43%CABACabaletta Bio-0.61%-9.92%-4.94%+4.47%+70.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.06-10.5%$0.09$0.04▼$0.36$15.35M2.4957.14 million shs49.26 million shsBCRXBioCryst Pharmaceuticals$8.74-0.3%$9.17$6.00▼$11.31$2.22B0.575.17 million shs2.57 million shsCABACabaletta Bio$3.44+5.2%$3.17$1.26▼$4.23$382.96M3.183.28 million shs3.29 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics0.00%0.00%0.00%0.00%-80.12%BCRXBioCryst Pharmaceuticals-2.23%-0.34%-7.68%+20.80%-15.43%CABACabaletta Bio-0.61%-9.92%-4.94%+4.47%+70.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAPAdaptimmune Therapeutics 1.75Reduce$0.50763.56% UpsideBCRXBioCryst Pharmaceuticals 2.75Moderate Buy$20.70136.84% UpsideCABACabaletta Bio 2.57Moderate Buy$15.50350.58% UpsideCurrent Analyst Ratings BreakdownLatest BCRX, ADAP, and CABA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026CABACabaletta Bio Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$2.00 ➝ $4.005/7/2026BCRXBioCryst Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$25.00 ➝ $28.005/7/2026BCRXBioCryst Pharmaceuticals WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$22.00 ➝ $21.005/6/2026BCRXBioCryst Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $16.005/4/2026CABACabaletta Bio Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$30.004/20/2026CABACabaletta Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/24/2026CABACabaletta Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $16.003/24/2026CABACabaletta Bio Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$14.00 ➝ $13.003/4/2026BCRXBioCryst Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Hold (C)(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAPAdaptimmune Therapeutics$178.03M0.09N/AN/A$0.05 per share1.16BCRXBioCryst Pharmaceuticals$885.72M2.51$1.21 per share7.24($2.18) per share-4.01CABACabaletta BioN/AN/AN/AN/A$0.93 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAPAdaptimmune Therapeutics-$70.81M-$0.65N/AN/AN/A-260.82%-163.73%-75.83%N/ABCRXBioCryst Pharmaceuticals$263.86M-$1.78N/A27.31N/A-51.71%-76.36%60.12%8/3/2026 (Estimated)CABACabaletta Bio-$167.86M-$1.96N/AN/AN/AN/A-131.58%-96.46%8/6/2026 (Estimated)Latest BCRX, ADAP, and CABA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CABACabaletta Bio-$0.41-$0.39+$0.02-$0.39$1.67 millionN/A5/6/2026Q1 2026BCRXBioCryst Pharmaceuticals$0.06-$2.98-$3.04-$2.98$151.12 million$156.41 million3/23/2026Q4 2025CABACabaletta Bio-$0.45-$0.40+$0.05-$0.40N/AN/A2/26/2026Q4 2025BCRXBioCryst Pharmaceuticals$0.07$1.12+$1.05$1.12$151.32 million$163.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/ABCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ACABACabaletta BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAPAdaptimmune TherapeuticsN/A1.521.29BCRXBioCryst PharmaceuticalsN/A1.911.88CABACabaletta BioN/A2.952.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAPAdaptimmune Therapeutics31.37%BCRXBioCryst Pharmaceuticals85.88%CABACabaletta BioN/AInsider OwnershipCompanyInsider OwnershipADAPAdaptimmune Therapeutics12.44%BCRXBioCryst Pharmaceuticals5.10%CABACabaletta Bio6.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAPAdaptimmune Therapeutics490265.05 million232.08 millionOptionableBCRXBioCryst Pharmaceuticals530254.16 million241.20 millionOptionableCABACabaletta Bio50111.33 million104.16 millionOptionableBCRX, ADAP, and CABA HeadlinesRecent News About These CompaniesIs Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?May 20 at 10:40 AM | zacks.comCabaletta Bio (CABA) Upgraded to Buy: Here's WhyMay 18 at 1:01 PM | zacks.comCabaletta Bio Inc Ordinary Shares CABAMay 17 at 5:53 PM | morningstar.comMFinancial Comparison: Bicycle Therapeutics (NASDAQ:BCYC) versus Cabaletta Bio (NASDAQ:CABA)May 16, 2026 | americanbankingnews.comCabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 14, 2026 | globenewswire.comCabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual MeetingMay 14, 2026 | globenewswire.comCabaletta Bio (CABA) Expected to Announce Earnings on ThursdayMay 14, 2026 | americanbankingnews.comCabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Rating of "Moderate Buy" from AnalystsMay 8, 2026 | marketbeat.comCabaletta Bio prices $150 million public offeringMay 5, 2026 | thepharmaletter.comTCabaletta Bio Shares Rise After $150M Underwritten Offering PricesMay 5, 2026 | marketwatch.comCABA stock on track for best day in 6 months after positive early results from cell therapy trialMay 5, 2026 | msn.comCabaletta Bio (NASDAQ:CABA) Receives "Overweight" Rating from Cantor FitzgeraldMay 4, 2026 | marketbeat.comCabaletta Bio Announces Pricing of $150 Million Underwritten OfferingMay 4, 2026 | globenewswire.comCabaletta Bio, Inc. $CABA Shares Bought by Jennison Associates LLCMay 3, 2026 | marketbeat.comStock Traders Buy High Volume of Call Options on Cabaletta Bio (NASDAQ:CABA)April 29, 2026 | marketbeat.comCellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-celApril 28, 2026 | businesswire.comCabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-celApril 28, 2026 | globenewswire.comCabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual ...April 28, 2026 | markets.businessinsider.comCabaletta Bio, Inc. to Present New Data on Rese-cel at ASGCT 2026 Annual MeetingApril 27, 2026 | quiverquant.comQCabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual MeetingApril 27, 2026 | globenewswire.comAAN 2026: Phase I/II success for rese-cel in gMG signals potential amid competitionApril 22, 2026 | yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCRX, ADAP, and CABA Company DescriptionsAdaptimmune Therapeutics NASDAQ:ADAPAdaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.BioCryst Pharmaceuticals NASDAQ:BCRX$8.74 -0.03 (-0.34%) Closing price 04:00 PM EasternExtended Trading$8.77 +0.03 (+0.34%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Cabaletta Bio NASDAQ:CABA$3.44 +0.17 (+5.20%) Closing price 04:00 PM EasternExtended Trading$3.39 -0.05 (-1.42%) As of 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
